Butylphthalide is a Small Molecule owned by CSPC NBP Pharmaceutical, and is involved in 6 clinical trials, of which 1 was completed, 2 are ongoing, and 3 are planned.
Butylphthalide can enhance the level of Nitric oxide (NO) and prostaglandins I2 (PGI2) of endothelium in blood vessel of brain, reduces the concentration of inner cellular calcium, inhibits glutamate release, reduces the content of arachidonate, inhibits radicals and increases the activities of antioxidases and is effecitive on the multi-pathological links of ischemic stroke. It has anti-brain ischemia effect and rate of the blood stream in the cerebral ischemic area and inhibits enzymes mediating inflammatory processes. The drug candidate increases the amount of capillary vessels in the ischemic area by reducing brain edema, improves the brain energy metabolism and inhibit the formation of thrombosis. Thus, butylphthalide (NBP) prevents the renarrowing of blood vessels. It acts by suppressing the expression of TNF-aplha and nuclear factor KB which increases the protein level of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1). Nrf2 activation reduces postinsult neuronal damage by promotion of anti-inflammatory and prosurvival genes which results in the alleviation of disease condition.
The revenue for Butylphthalide is expected to reach a total of $9.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Butylphthalide NPV Report.
Butylphthalide is originated and owned by CSPC NBP Pharmaceutical. CSPC Pharmaceutical Group is the other company associated in development or marketing of Butylphthalide.
Butylphthalide (n-butylphthalide) is an extract from seeds of Apium graveolens Linn (Chinese celery), acts as anti-ischemic agent. It is formulated as capsules for oral route and injectable solution for intravenous route of administration. Butylphthalide is indicated for the treatment of mild to moderate acute ischemic stroke.
DL-3-n-butylphthalide is under development for the treatment of nab-paclitaxel induced toxic neuropathy in metastatic breast cancer patients and vascular dementia caused by ischemic stroke. It was also under development for amyotrophic lateral sclerosis.
CSPC Pharmaceutical Group Overview
CSPC Pharmaceutical Group (CSPC) is a pharmaceutical company, which provides innovative, common generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and childhood acute lymphoblastic leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
The company reported revenues of (Renminbi) CNY27,866.9 million for the fiscal year ended December 2021 (FY2021), an increase of 11.7% over FY2020. In FY2021, the company’s operating margin was 24.5%, compared to an operating margin of 25.6% in FY2020. In FY2021, the company recorded a net margin of 20.1%, compared to a net margin of 20.7% in FY2020. The company reported revenues of CNY7,885.5 million for the third quarter ended September 2022, an increase of 1.9% over the previous quarter.
Quick View – Butylphthalide
|Highest Development Stage|